{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:16:44Z","timestamp":1792545404287,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.psychres.2025.116670","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:30:44Z","timestamp":1754433044000},"page":"116670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative efficacy and safety of clozapine vs. risperidone in schizophrenia and related disorders: An updated systematic review"],"prefix":"10.1016","volume":"351","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-0524","authenticated-orcid":false,"given":"Claudia","family":"Asenjo-Lobos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2239-6248","authenticated-orcid":false,"given":"Marcelo","family":"Arancibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Cort\u00e9s-Jofr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-5549","authenticated-orcid":false,"given":"Eva","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.psychres.2025.116670_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3928\/02793695-20220112-02","article-title":"Using relapse prevention interventions to maintain remission and minimize relapse rates for individuals with schizophrenia: a scoping review","volume":"60","author":"Abu Sabra","year":"2022","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"issue":"12","key":"10.1016\/j.psychres.2025.116670_bib0002","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/obr.12934","article-title":"Effects of antidepressant and antipsychotic use on weight gain: a systematic review","volume":"20","author":"Alonso-Pedrero","year":"2019","journal-title":"Obes. Rev."},{"issue":"11","key":"10.1016\/j.psychres.2025.116670_bib0003","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","author":"Asenjo-Lobos","year":"2010","journal-title":"Cochrane Database Systemat. Rev."},{"issue":"12","key":"10.1016\/j.psychres.2025.116670_bib0004","article-title":"Clozapine versus risperidone for people with schizophrenia","author":"Asenjo-Lobos","year":"2018","journal-title":"Cochrane Database Systemat. Rev."},{"issue":"8","key":"10.1016\/j.psychres.2025.116670_bib0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiat."},{"issue":"6","key":"10.1016\/j.psychres.2025.116670_bib0006","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"Am. J. Psychiat."},{"issue":"4","key":"10.1016\/j.psychres.2025.116670_bib0007","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study","volume":"155","author":"Bondolfi","year":"1998","journal-title":"Am. J. Psychiat."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0008","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am. J. Psychiat."},{"issue":"4","key":"10.1016\/j.psychres.2025.116670_bib0009","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr Bull."},{"issue":"5","key":"10.1016\/j.psychres.2025.116670_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0269881110376685","article-title":"Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis","volume":"25","author":"Chung","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0011","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiat."},{"issue":"5","key":"10.1016\/j.psychres.2025.116670_bib0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"issue":"4","key":"10.1016\/j.psychres.2025.116670_bib0013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother. Psychosom."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/acps.13758","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis","volume":"151","author":"De","year":"2025","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2025.116670_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","volume":"2014","author":"Divac","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.psychres.2025.116670_bib0016","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00406-023-01654-2","article-title":"A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia","volume":"274","author":"Dong","year":"2024","journal-title":"Eur. Arch. Psychiatry. Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.psychres.2025.116670_bib0017","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/02698811231190864","article-title":"QTc prolongation in patients with schizophrenia taking antipsychotics: prevalence and risk factors","volume":"37","author":"Du","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0018","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2215-0366(23)00366-8","article-title":"Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data","volume":"11","author":"Efthimiou","year":"2024","journal-title":"Lancet Psychiat."},{"issue":"18","key":"10.1016\/j.psychres.2025.116670_bib0019","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hup.1176","article-title":"Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial","volume":"26","author":"Ghaleiha","year":"2011","journal-title":"Human Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41537-023-00356-x","article-title":"Influencing factors of medication adherence in schizophrenic patients: a meta-analysis","volume":"9","author":"Guo","year":"2023","journal-title":"Schizophrenia (Heidelb)."},{"issue":"7650","key":"10.1016\/j.psychres.2025.116670_bib0022","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.psychres.2025.116670_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.38358","article-title":"Comparative effectiveness of antipsychotics in patients with Schizophrenia spectrum disorder","volume":"7","author":"Hamina","year":"2024","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0278-5846(94)90029-9","article-title":"Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial","volume":"18","author":"Heinrich","year":"1994","journal-title":"Prog. Neuro-Psychopharmacol. Biologic. Psychiat."},{"key":"10.1016\/j.psychres.2025.116670_bib0025","unstructured":"Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2011. Chapter 8: assessing risk of bias in included studies, in: Higgins, J.P.T., Sterne, J.A. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions, 5.1.0 ed. The Cochrane Collaboration."},{"key":"10.1016\/j.psychres.2025.116670_bib0026","unstructured":"Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2022a. Chapter 9: interpreting results and undertaking subgroup analyses, in: Higgins, J.P.T., Sterne, J.A. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. Cochrane Collaboration."},{"key":"10.1016\/j.psychres.2025.116670_bib0027","unstructured":"Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2022b. Chapter 10: exploring heterogeneity, in: Higgins, J.P.T., Sterne, J.A. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. The Cochrane Collaboration."},{"key":"10.1016\/j.psychres.2025.116670_bib0028","unstructured":"Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2022c. Chapter 10: funnel plots, in: Higgins, J.P.T., Sterne, J.A. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. The Cochrane Collaboration."},{"key":"10.1016\/j.psychres.2025.116670_bib0029","unstructured":"Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2022d. Chapter 10: measuring heterogeneity, in: Higgins, J.P.T., Sterne, J.A. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. Cochrane Collaboration."},{"key":"10.1016\/j.psychres.2025.116670_bib0030","unstructured":"Higgins JPT, T.J., Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), 2022e. Chapter 10: random-effects model, in: Higgins, J.P.T., Sterne, J.A. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. The Cochrane Collaboration."},{"issue":"10202","key":"10.1016\/j.psychres.2025.116670_bib0031","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.psychres.2025.116670_bib0032","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with Chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiat."},{"issue":"3","key":"10.1016\/j.psychres.2025.116670_bib0033","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2015.2966","article-title":"The role of clozapine in treatment-resistant schizophrenia","volume":"73","author":"Kane","year":"2016","journal-title":"JAMA Psychiat."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0034","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiat."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0035","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9896","key":"10.1016\/j.psychres.2025.116670_bib0036","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"issue":"2-3","key":"10.1016\/j.psychres.2025.116670_bib0037","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0038","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/wps.21089","article-title":"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis","volume":"22","author":"Leucht","year":"2023","journal-title":"World Psychiat."},{"issue":"12","key":"10.1016\/j.psychres.2025.116670_bib0039","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.psychres.2025.116670_bib0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiat."},{"issue":"5","key":"10.1016\/j.psychres.2025.116670_bib0041","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","article-title":"INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia","volume":"12","author":"McCutcheon","year":"2025","journal-title":"Lancet Psychiat."},{"issue":"5","key":"10.1016\/j.psychres.2025.116670_bib0042","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1176\/appi.ajp.162.5.1013","article-title":"The effects of clozapine and risperidone on spatial working memory in schizophrenia","volume":"162","author":"McGurk","year":"2005","journal-title":"Am. J. Psychiat."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug-related weight gain and its treatment","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am. J. Psychia."},{"issue":"3","key":"10.1016\/j.psychres.2025.116670_bib0044","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clinic. Schizophrenia Relat. Psychoses"},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch Gen. Psychiat."},{"issue":"6","key":"10.1016\/j.psychres.2025.116670_bib0046","first-page":"425","article-title":"Effect of risperidone and clozapine on cognitive function in patients with schizophrenia using maze test and WSCT [\u8ff7\u5bab\u6d4b\u9a8c\u4e0eWcst\u68c0\u6d4b\u5229\u57f9\u916e\u548c\u6c2f\u6c2e\u5e73\u5bf9\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\u8ba4\u77e5\u529f\u80fd\u7684\u5f71\u54cd]","volume":"21","author":"Mi","year":"2008","journal-title":"Shandong Archiv. Psychiat. [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"5","key":"10.1016\/j.psychres.2025.116670_bib0047","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.6.5.803","article-title":"Risperidone: a review","volume":"6","author":"M\u00f6ller","year":"2005","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.psychres.2025.116670_bib0048","series-title":"Psychosis and schizophrenia in adults: prevention and management","year":"2025"},{"issue":"11-12","key":"10.1016\/j.psychres.2025.116670_bib0049","first-page":"77","article-title":"Positive and negative syndrome scale (PANSS) training: challenges, solutions, and future directions","volume":"14","author":"Opler","year":"2017","journal-title":"Innov Clin. Neurosci."},{"issue":"10039","key":"10.1016\/j.psychres.2025.116670_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.psychres.2025.116670_bib0051","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a reexamination","volume":"62","author":"Palmer","year":"2005","journal-title":"Arch. Gen. Psychiat."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0052","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiat."},{"issue":"3","key":"10.1016\/j.psychres.2025.116670_bib0053","first-page":"198","article-title":"Comparison of quality of life of schizophrenic outpatients treated with Risperdal or Clozapine","volume":"16","author":"Ren","year":"2002","journal-title":"Chinese Ment. Health J."},{"issue":"2-3","key":"10.1016\/j.psychres.2025.116670_bib0054","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res."},{"issue":"11","key":"10.1016\/j.psychres.2025.116670_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111577","article-title":"A systematic review on the effectiveness of antipsychotic drugs on the quality of life of patients with schizophrenia","volume":"13","author":"Sampogna","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.psychres.2025.116670_bib0056","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2024.12.015","article-title":"Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: a retrospective chart review","volume":"275","author":"Sanahan","year":"2025","journal-title":"Schizophr Res."},{"issue":"4","key":"10.1016\/j.psychres.2025.116670_bib0057","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S2215-0366(25)00001-X","article-title":"Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis","volume":"12","author":"Schneider-Thoma","year":"2025","journal-title":"Lancet Psychiat."},{"key":"10.1016\/j.psychres.2025.116670_bib0058","series-title":"Chapter 12: Interpreting results and drawing conclusions, Cochrane Handbook for Systematic Reviews of Interventions","first-page":"359","author":"Sch\u00fcnemann","year":"2011"},{"issue":"4","key":"10.1016\/j.psychres.2025.116670_bib0059","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S2215-0366(25)00032-X","article-title":"Clozapine and treatment-resistant schizophrenia: efficacy versus effectiveness","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiat."},{"issue":"8","key":"10.1016\/j.psychres.2025.116670_bib0060","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0061","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychia."},{"issue":"1-3","key":"10.1016\/j.psychres.2025.116670_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \"just the facts\" 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr Res."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0063","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41537-025-00570-9","article-title":"Determinants of patient satisfaction in clozapine users: results from the Clozapine International Consortium (CLOZIN)","volume":"11","author":"van der Horst","year":"2025","journal-title":"Schizophrenia (Heidelb)."},{"issue":"1","key":"10.1016\/j.psychres.2025.116670_bib0064","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl. Psychiat."},{"issue":"2","key":"10.1016\/j.psychres.2025.116670_bib0065","first-page":"7","article-title":"Risperdal and chlorine oxygen level treatment of schizophrenia, double-blind, controlled study [\u7ef4\u601d\u901a\u4e0e\u6c2f\u6c27\u5e73\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u53cc\u76f2\u5bf9\u7167\u7814]","volume":"12","author":"Zhang","year":"1999","journal-title":"Shandong Archiv. Psychia."},{"key":"10.1016\/j.psychres.2025.116670_bib0066","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr. Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517812500318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517812500318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:43:53Z","timestamp":1778946233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016517812500318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":66,"alternative-id":["S016517812500318X"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116670","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of clozapine vs. risperidone in schizophrenia and related disorders: An updated systematic review","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116670"}}